Pfizer, BioNTech COVID-19 vaccine authorized in Canada for children 5 to 11 years of age


Shares of Pfizer Inc. PFE, +0.56% rose 2.1% and of Germany-based partner BioNTech SE BNTX, +3.80% climbed 4.2% in morning trading Friday, after Health Canada authorized use of the companies’ COVID-19 vaccine in children 5 to 11 years old. That’s the first vaccine authorized in Canada for that age group. The companies’ vaccine has been authorized for children 12 to 15 years old since May and for people at least 16 years old since December. The news comes on the same day that the U.S. Food and Drug Administration OK’d the use of COVID-19 booster shots for both the Pfizer-BioNTech and Moderna Inc. COVID-19 vaccines for all adults. Pfizer’s stock has gained 7.6% over the past three months while BioNTech shares have shed 14.0%, and the S&P 500 SPX, +0.10% has tacked on 6.9%.

This article was originally published by Read the original article here.

Previous articleMarket Snapshot: Dow off 200 points as jitters over rising COVID-19 cases in Europe weigh on bulls
Next articleCoronavirus Update: Austria imposes wider lockdown, makes vaccination mandatory


Please enter your comment!
Please enter your name here